IL80944A - A factor in the formation of blood vessels in a human placenta capable of inducing protease synthesis in the inner lining of capillary cells, DNA synthesis. And migration of materials - Google Patents

A factor in the formation of blood vessels in a human placenta capable of inducing protease synthesis in the inner lining of capillary cells, DNA synthesis. And migration of materials

Info

Publication number
IL80944A
IL80944A IL8094486A IL8094486A IL80944A IL 80944 A IL80944 A IL 80944A IL 8094486 A IL8094486 A IL 8094486A IL 8094486 A IL8094486 A IL 8094486A IL 80944 A IL80944 A IL 80944A
Authority
IL
Israel
Prior art keywords
angiogenic factor
protein
amino acid
angiogenic
paf
Prior art date
Application number
IL8094486A
Other languages
English (en)
Hebrew (he)
Other versions
IL80944A0 (en
Original Assignee
Synergen Inc Boulder Colo U S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27420052&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IL80944(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Synergen Inc Boulder Colo U S filed Critical Synergen Inc Boulder Colo U S
Publication of IL80944A0 publication Critical patent/IL80944A0/xx
Publication of IL80944A publication Critical patent/IL80944A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C12N15/625—DNA sequences coding for fusion proteins containing a sequence coding for a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/035—Fusion polypeptide containing a localisation/targetting motif containing a signal for targeting to the external surface of a cell, e.g. to the outer membrane of Gram negative bacteria, GPI- anchored eukaryote proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Cardiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Plant Pathology (AREA)
  • Toxicology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
IL8094486A 1985-12-17 1986-12-11 A factor in the formation of blood vessels in a human placenta capable of inducing protease synthesis in the inner lining of capillary cells, DNA synthesis. And migration of materials IL80944A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US80987385A 1985-12-17 1985-12-17
US88855486A 1986-07-16 1986-07-16
US89582986A 1986-08-12 1986-08-12

Publications (2)

Publication Number Publication Date
IL80944A0 IL80944A0 (en) 1987-03-31
IL80944A true IL80944A (en) 1994-10-07

Family

ID=27420052

Family Applications (1)

Application Number Title Priority Date Filing Date
IL8094486A IL80944A (en) 1985-12-17 1986-12-11 A factor in the formation of blood vessels in a human placenta capable of inducing protease synthesis in the inner lining of capillary cells, DNA synthesis. And migration of materials

Country Status (15)

Country Link
EP (1) EP0226181B1 (fr)
JP (1) JPH10262668A (fr)
KR (1) KR960015442B1 (fr)
AT (1) ATE107315T1 (fr)
AU (2) AU6774887A (fr)
DE (1) DE3689921T2 (fr)
DK (1) DK424387A (fr)
ES (1) ES2056787T3 (fr)
FI (1) FI93843C (fr)
IE (1) IE863281L (fr)
IL (1) IL80944A (fr)
NO (1) NO177859C (fr)
NZ (1) NZ218631A (fr)
PT (1) PT83939B (fr)
WO (1) WO1987003885A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5852177A (en) * 1987-02-24 1998-12-22 Takeda Chemical Industries, Ltd. Basic fibroblast growth factor (bFGF) muteins
US4900673A (en) * 1988-03-28 1990-02-13 President And Fellows Of Harvard College Mutant human angiogenin (angiogenesis factor with superior angiogenin activity) genes therefor and methods of expression
EP0444149A4 (en) * 1988-11-07 1991-10-09 Synergen Incorporated High molecular weight human angiogenic factors
WO1993015753A1 (fr) * 1992-02-14 1993-08-19 Kaken Pharmaceutical Co., Ltd. Medicament contre les maladies des voies aeriennes
GB9203533D0 (en) * 1992-02-19 1992-04-08 Erba Carlo Spa Use of the conjugate between a fibroblast growth factor and a saporin in treating ocular pathologies
US6749850B1 (en) * 1999-08-18 2004-06-15 The General Hospital Corporation Methods, compositions and kits for promoting recovery from damage to the central nervous system
WO2003106663A1 (fr) 2002-06-18 2003-12-24 エーザイ株式会社 Adipocytes de culture primaire utilises en therapie genique
EP1933852B1 (fr) * 2005-09-27 2018-12-19 TissueTech, Inc. Preparations de membrane amniotique et compositions purifiees, et procedes d'utilisation
CN111100191A (zh) * 2018-10-26 2020-05-05 神威药业集团有限公司 源于人胎盘的活性蛋白质或多肽及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4225670A (en) * 1978-12-29 1980-09-30 Monsanto Company Production of tumor angiogenesis factor by cell culture
US4209587A (en) * 1978-12-29 1980-06-24 Monsanto Company Production of tumor angiogenesis factor by cell culture
DE3110560A1 (de) * 1981-03-18 1982-10-14 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen "angiotropine der leukozyten und des entzuendungsgewebes: eine neue klasse natuerlicher chemotropischer mitogene fuer das richtungswachstum von blutgefaessen und zur neovaskularisierung von geweben"
US4529590A (en) * 1982-12-27 1985-07-16 Leveen Robert F Production of angiogenetic factor
GB2146523B (en) * 1983-09-13 1987-01-07 Ward Page Faulk Preparation for stimulating growth of blood vessels prepared from amniochorionic tissue and macrophages
EP0593065B1 (fr) * 1985-09-12 2002-08-21 Scios Inc. Facteurs de croissance de fibroblastes recombinants
IL81650A0 (en) * 1986-02-24 1987-09-16 Robapharm Ag Purified human angiogenic factor,method for its preparation and pharmaceutical preparations

Also Published As

Publication number Publication date
WO1987003885A1 (fr) 1987-07-02
DK424387D0 (da) 1987-08-14
EP0226181B1 (fr) 1994-06-15
FI93843C (fi) 1995-06-12
ES2056787T3 (es) 1994-10-16
ATE107315T1 (de) 1994-07-15
FI93843B (fi) 1995-02-28
IE863281L (en) 1987-06-17
JPH10262668A (ja) 1998-10-06
AU7629991A (en) 1991-08-08
PT83939B (pt) 1989-05-31
NO177859B (no) 1995-08-28
EP0226181A3 (en) 1989-03-08
DK424387A (da) 1987-08-14
AU650649B2 (en) 1994-06-30
FI882891A0 (fi) 1988-06-16
NO873437L (no) 1987-08-14
PT83939A (en) 1987-01-01
KR880700820A (ko) 1988-04-12
NO873437D0 (no) 1987-08-14
IL80944A0 (en) 1987-03-31
EP0226181A2 (fr) 1987-06-24
AU6774887A (en) 1987-07-15
NZ218631A (en) 1991-07-26
DE3689921T2 (de) 1994-09-22
FI882891A (fi) 1988-06-16
NO177859C (no) 1995-12-06
KR960015442B1 (ko) 1996-11-14
DE3689921D1 (de) 1994-07-21

Similar Documents

Publication Publication Date Title
US4994559A (en) Human basic fibroblast growth factor
US5026839A (en) DNA encoding a basic fibroblast growth factor
AU729880C (en) Recombinant vascular endothelial cell growth factor D (VEGF-D)
EP0154434B1 (fr) Facteur humain de transformation de croissance et précurseur ou fragment de celui-ci, cellules, ADN, vecteurs et méthodes pour leur production, compositions et produits contenant ceux-ci et anticorps et méthodes diagnostiques en relation avec ceux-ci
IL89033A (en) Bifunctional growth modulating glycoprotein named amphiregulin and its production
US5115096A (en) Amphiregulin: a bifunctional growth modulating glycoprotein
CA2094045A1 (fr) Mitogene liant l'heparine et presentant une homologie avec les egf
JP4493854B2 (ja) リガンドの生物学的活性を増強する方法
CA1341516C (fr) Preparation du facteur x111a par manipulation genetique
EP0226181B1 (fr) Facteur angiogénique de placenta humain capable de stimuler la synthèse capillaire de protéase de cellules endothéliales, la synthèse d'ADN et la migration
JP2770926B2 (ja) 毛管内皮細胞プロテアーゼ合成、ｄｎａ合成および遊走を促進することの出来るヒト胎盤血管形成誘導因子
JP3375997B2 (ja) 血管内皮細胞増殖促進剤
US6235884B1 (en) Heparin binding mitogen with homology to epidermal growth factor (EGF)
PT89511B (pt) Processo para a preparacao de anfiregulina, um regulador bifuncional do crescimento de celulas

Legal Events

Date Code Title Description
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees